welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the recipients of Route 79, The Duchenne Scholarship Program. This is the second year of the scholarship program which was created to recognize exceptional individuals with Duchenne muscular dystrophy as they pursue their post-secondary education. Twenty-three recipients were chosen by an independent selection committee comprised of Duchenne community members based on each applicant’s community involvement and a personal essay. Each of the students will receive scholarships of up to $5,000.
rareRelated
-
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)The main purposes of this study are to s...
-
Study of SRP-4045 and SRP-4053 in DMD PatientsThe main objective of this study is to e...
-
Mother-caregivers of Children With Duchenne Muscular DystrophyThe incidence of Duchenne Muscular Dystr...
-
For Many Boys With Duchenne Muscular Dystrophy, Bright Hope Lies Just Beyond ReachLucas was 5 before his parents, Bill and...
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duc...The purpose of this study is to evaluate...
-
Solid Biosciences Provides SGT-001 Program UpdateCAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE...
-
Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) PatientsThis Phase I/II of the clinical trial is...
-
First targeted treatment success for Duchenne muscular dystrophyhttps://www.youtube.com/watch?v=tkxTn46_...
-
A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged 2 to 5 years with nonsense mutation ...Nonsense mutation Duchenne muscular dyst...
-
Sarepta Therapeutics Announces that Phase 1/2a Duchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial...Sarepta Therapeutics, Inc., a commercia...
